mitoxantrone liposome + cytarabine + venetoclax

This combination regimen consists of a liposomal formulation of mitoxantrone, the antimetabolite cytarabine, and the BCL-2 inhibitor venetoclax. It is primarily investigated for the treatment of acute myeloid leukemia (AML), particularly in relapsed or refractory settings. Mitoxantrone liposome (PLM60) is a nanoparticle-based delivery system designed to provide sustained release and reduced cardiotoxicity compared to conventional mitoxantrone; it acts as a DNA intercalator and type II topoisomerase inhibitor. Cytarabine is a pyrimidine analog that interferes with DNA synthesis by inhibiting DNA polymerase. Venetoclax is a selective small-molecule inhibitor of the anti-apoptotic protein BCL-2, which sensitizes leukemia cells to apoptosis. The regimen is being evaluated in clinical trials sponsored by institutions such as Sichuan Provincial People's Hospital to improve remission rates in difficult-to-treat AML populations.

Brand names

Duoenyi + Venclexta

Other names

mitoxantrone hydrochloride liposome injection + cytarabine + venetoclaxLipo-MIT + Ara-C + venetoclax